Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Apremilast improved symptoms in patients with severe skin conditions.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Tofacitinib may help regrow hair in alopecia areata patients.

Efalizumab can cause unexpected excessive hair growth.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.

JAK inhibitors show promise in treating difficult skin diseases.

Ruxolitinib treatment may cause eyelash growth.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

JAK inhibitors show promise for treating various skin diseases.

Tofacitinib treatment for hair loss may worsen acne.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Tislelizumab can cause cutaneous lupus erythematosus.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

The compound zishenqing formula is effective and safe for treating mild to moderate systemic lupus erythematosus.